Last reviewed · How we verify

Full dose of DOAC — Competitive Intelligence Brief

Full dose of DOAC (Full dose of DOAC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct oral anticoagulant (DOAC). Area: Cardiovascular.

phase 3 Direct oral anticoagulant (DOAC) Factor Xa or Factor IIa (thrombin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Full dose of DOAC (Full dose of DOAC) — University Hospital, Brest. Direct oral anticoagulants (DOACs) inhibit specific clotting factors to prevent blood clot formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Full dose of DOAC TARGET Full dose of DOAC University Hospital, Brest phase 3 Direct oral anticoagulant (DOAC) Factor Xa or Factor IIa (thrombin)
Pradaxa dabigatran etexilate Generic (originally Boehringer Ingelheim) marketed Direct oral anticoagulant (DOAC) — direct thrombin inhibitor Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] 2010-10-19
Rivaroxaban, Dabigatran Rivaroxaban, Dabigatran University Hospital, Grenoble marketed Direct oral anticoagulant (DOAC) Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran)
Rivaroxaban, dabigatran, apixaban, or edoxaban Rivaroxaban, dabigatran, apixaban, or edoxaban Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec marketed Direct oral anticoagulant (DOAC) Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)
Dabigatran; Rivaroxaban Dabigatran; Rivaroxaban University Hospital, Grenoble marketed Direct oral anticoagulant (DOAC) Dabigatran: Factor IIa (thrombin); Rivaroxaban: Factor Xa
Continuous DOAC therapy Continuous DOAC therapy Johns Hopkins University phase 3 Direct oral anticoagulant (DOAC) Factor Xa or Factor IIa (thrombin)
Dabigatran and Apixaban Dabigatran and Apixaban University of Sao Paulo General Hospital phase 3 Direct oral anticoagulant (DOAC) Dabigatran: Factor IIa (thrombin); Apixaban: Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct oral anticoagulant (DOAC) class)

  1. University Hospital, Grenoble · 2 drugs in this class
  2. Centre Hospitalier Universitaire de Nīmes · 1 drug in this class
  3. Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · 1 drug in this class
  4. Johns Hopkins University · 1 drug in this class
  5. University Hospital, Brest · 1 drug in this class
  6. University of Sao Paulo General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Full dose of DOAC — Competitive Intelligence Brief. https://druglandscape.com/ci/full-dose-of-doac. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: